Epstein Danny, Badarni Karawan, Bar-Lavie Yaron
Critical Care Division, Rambam Health Care Campus, Haifa 3109601, Israel.
Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa 3525433, Israel.
Antibiotics (Basel). 2024 Dec 22;13(12):1233. doi: 10.3390/antibiotics13121233.
: Sepsis, a life-threatening organ dysfunction caused by a dysregulated host response to infection, remains a major challenge in ICUs. This study evaluated whether combining haemoadsorption therapy with continuous renal replacement therapy (CRRT) reduces ICU and short-term mortality in patients with severe septic shock and acute kidney injury (AKI) requiring CRRT. : A single-centre retrospective cohort study was conducted at Rambam Health Care Campus, Haifa, Israel, from January 2018 to February 2024. Data were collected from ICU patients with severe septic shock and AKI requiring CRRT. Patients were divided into two groups: those receiving haemoadsorption therapy with CRRT and those receiving CRRT alone. Primary and secondary endpoints included ICU, 30 and 60-day mortality, vasopressor dependency index (VDI), and lactate levels. : Out of 545 patients with septic shock, 133 developed AKI requiring CRRT, and 76 met the inclusion criteria. The haemoadsorption group ( = 47) showed significant reductions in blood lactate levels and VDI after 24 h compared to the CRRT alone group ( = 29). ICU mortality was significantly lower in the haemoadsorption group (34.0% vs. 65.5%, = 0.008), as was 30 and 60-day mortality (34.0% vs. 62.1%, = 0.02, and 48.9% vs. 75.9%, = 0.002). Multivariate analysis confirmed haemoadsorption therapy as independently associated with lower ICU and 30-day but not 60-day mortality. : Haemoadsorption therapy combined with CRRT in patients with severe septic shock and AKI requiring CRRT is associated with improved lactate clearance, reduced vasopressor requirements, and lower ICU and 30-day mortality. Further high-quality randomized controlled trials are needed to confirm these findings.
脓毒症是由宿主对感染的反应失调引起的危及生命的器官功能障碍,仍然是重症监护病房面临的主要挑战。本研究评估了血液吸附疗法与连续性肾脏替代疗法(CRRT)联合使用是否能降低需要CRRT的严重脓毒性休克和急性肾损伤(AKI)患者的重症监护病房死亡率和短期死亡率。
在以色列海法的兰巴姆医疗保健校园进行了一项单中心回顾性队列研究,时间从2018年1月至2024年2月。收集了需要CRRT的重症脓毒性休克和AKI的重症监护病房患者的数据。患者分为两组:接受血液吸附疗法联合CRRT的患者和仅接受CRRT的患者。主要和次要终点包括重症监护病房、30天和60天死亡率、血管升压药依赖指数(VDI)和乳酸水平。
在545例脓毒性休克患者中,133例发生了需要CRRT的AKI,76例符合纳入标准。与仅接受CRRT的组(n = 29)相比,血液吸附组(n = 47)在24小时后血液乳酸水平和VDI显著降低。血液吸附组的重症监护病房死亡率显著更低(34.0% 对65.5%,P = 0.008),30天和60天死亡率也是如此(34.0% 对62.1%,P = 0.02,48.9% 对75.9%,P = 0.002)。多变量分析证实血液吸附疗法与更低的重症监护病房和30天死亡率独立相关,但与60天死亡率无关。
对于需要CRRT的严重脓毒性休克和AKI患者,血液吸附疗法联合CRRT与改善乳酸清除、减少血管升压药需求以及降低重症监护病房和30天死亡率相关。需要进一步的高质量随机对照试验来证实这些发现。